BOADICEA alternative: breast cancer risk model options and how they fit together

Short version. BOADICEA (the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm), delivered via the CanRisk web tool from the University of Cambridge, is the most comprehensive breast cancer risk model in mainstream clinical use. It integrates multiple genes, polygenic risk, mammographic density, hormonal and reproductive factors, and lifestyle variables. It is endorsed in NICE and NCCN guidelines and is well-validated. A true head-to-head replacement for BOADICEA does not exist today. Clinicians looking for "a BOADICEA alternative" are typically looking for something adjacent: an integrated pedigree management platform, a narrower focused BRCA1/BRCA2 carrier probability calculator, programmatic access via APIs, or AI-assisted clinical interpretation. Evagene integrates BRCAPRO from BayesMendel directly on the pedigree — it is not a BOADICEA reimplementation and does not aim to be. For services that need BOADICEA specifically, CanRisk remains the reference; Evagene can sit alongside it as the pedigree layer that feeds multiple tools.

What BOADICEA is and why it is widely used

BOADICEA was developed at the Centre for Cancer Genetic Epidemiology at the University of Cambridge by the group led by Antonis Antoniou and colleagues, building on earlier work by the same group and by international consortia. It has gone through several revisions, each expanding the model's coverage. The current implementation lives inside the CanRisk web tool, which provides the interface, pedigree entry, and reporting.

BOADICEA's coverage is the reason for its prominence. Rather than modelling BRCA1 and BRCA2 alone, it includes the major moderate-penetrance breast cancer genes: PALB2, CHEK2, ATM, BARD1, RAD51C, and RAD51D. It incorporates a polygenic risk score (PRS) derived from many common variants identified by genome-wide association studies, which meaningfully refines risk particularly for women without a strong monogenic family history. It accepts mammographic density as a risk factor, which is important for screening-intensity decisions. And it incorporates hormonal and reproductive factors (age at menarche, parity, age at first live birth, menopause status, hormone replacement therapy use, oral contraceptive use) and selected lifestyle variables such as body mass index and alcohol consumption.

The combination — multi-gene carrier probability, polygenic risk, density, hormonal and reproductive factors, lifestyle — is what gives BOADICEA its breadth. For a breast cancer genetics service asked to provide a comprehensive individualised risk assessment, BOADICEA is currently the most complete tool with mainstream guideline endorsement. NICE in the UK and NCCN in the US both cite it within their breast cancer risk assessment frameworks.

Why clinicians look for alternatives

The phrase "BOADICEA alternative" covers several different underlying questions. Being honest about which question is being asked matters, because different answers apply.

• "I want an integrated pedigree management platform." CanRisk is primarily a risk model interface. Services that want the pedigree to live inside a broader clinical genetics platform — with gesture drawing, disease annotation across many conditions, consanguinity analysis, batch risk screening, AI interpretation, and programmatic access — are looking for a pedigree platform first and a risk model second. That is a different product category.
• "I want a focused BRCA1/BRCA2 carrier probability tool." BOADICEA's breadth is overkill for some workflows. A service running a triage step to decide who gets BRCA testing may prefer BRCAPRO's narrower two-gene Bayesian estimate.
• "I want programmatic access." If the downstream use is an EHR integration, a research pipeline, or an AI agent that needs to submit a pedigree and retrieve a risk estimate, the workflow needs is primarily an API, not a web form.
• "I want AI-assisted clinical interpretation." Drafting a pre-test clinical summary, consolidating findings, framing family-communication letters — these are increasingly assisted by large language models. A service that wants this integrated into its risk workflow is looking for something BOADICEA does not set out to provide.
• "I want something that also handles non-breast cancers." BOADICEA models breast and ovarian cancer. A service that sees families with breast, colorectal, and pancreatic history in the same session wants a platform that runs Lynch and pancreatic models alongside breast, not a breast-specific tool.

None of these needs requires replacing BOADICEA. Most are about what surrounds BOADICEA in a modern workflow.

BOADICEA vs BRCAPRO: an honest comparison

BOADICEA and BRCAPRO are the two most-cited Bayesian breast cancer carrier probability tools. They have different scopes and different strengths. Being even-handed about both is useful, because clinicians do not need to pick a winner; they need to know which to reach for when.

The honest summary is that BOADICEA is the broader and more comprehensive tool. If a question requires any of its non-BRCAPRO ingredients — moderate-penetrance genes, polygenic risk, density, or hormonal factors — BOADICEA is the right tool. If the question is specifically about BRCA1/BRCA2 carrier probability from family history, BRCAPRO is a clean, focused, well-validated choice and is often faster to run.

In many breast cancer genetics services, both tools are used: BRCAPRO as a quick triage signal from the pedigree, BOADICEA for a comprehensive assessment when the clinical question warrants it. They are not competitors so much as complements.

Where Tyrer-Cuzick fits

Tyrer-Cuzick (IBIS) is the third model worth discussing. It estimates lifetime breast cancer risk rather than focusing on carrier probability, using hormonal and reproductive factors, family history, and optionally mammographic density. In the UK it is commonly used to decide screening intensity under NICE familial breast cancer guidance. Tyrer-Cuzick's BRCA carrier modelling is more limited than either BOADICEA's or BRCAPRO's, so most services do not use it for carrier probability decisions. Our Tyrer-Cuzick guide covers this in more detail.

What "a BOADICEA alternative" actually looks like in practice

When a service asks for a BOADICEA alternative, the practical need usually falls into one of a small number of patterns.

• Pedigree-first platform with integrated risk models. A single canvas where the pedigree is drawn once and risk models (BRCAPRO, MMRpro, PancPRO, Mendelian) run on it directly, with AI interpretation and programmatic access. Evagene occupies this pattern.
• Comprehensive multi-gene / polygenic / density / lifestyle risk. For this need, CanRisk remains the reference. No integrated platform currently replaces it. A sensible architecture is to use Evagene (or equivalent) as the pedigree layer, export the pedigree as GEDCOM or structured data, and feed it to CanRisk for the comprehensive assessment.
• Quick BRCA-focused carrier probability. BRCAPRO, ideally integrated into the pedigree environment so there is no re-entry step.
• Programmatic / agentic access. REST APIs, embeddable viewers, MCP servers for AI agents. Evagene addresses this; CanRisk does not primarily target this use.

The honest conclusion is that for comprehensive breast cancer risk assessment with polygenic scores and lifestyle factors, CanRisk/BOADICEA is the right tool. For integrated pedigree management with BRCAPRO and the other BayesMendel models as part of a broader clinical genetics workflow, Evagene is the right tool. Many services will want both.

How Evagene integrates BRCAPRO alongside BOADICEA

Evagene is not a BOADICEA implementation and does not aim to be. It is a browser-based clinical pedigree management platform that integrates BRCAPRO, MMRpro, and PancPRO from the BayesMendel suite, plus Mendelian inheritance calculators, running directly on the pedigree you have drawn or imported. For services whose BRCA1/BRCA2 carrier probability question can be answered by BRCAPRO, this gives a single-surface workflow: draw the pedigree, run BRCAPRO, review the results alongside the canvas, optionally have the AI interpretation engine draft a clinical summary.

For the same services that also want BOADICEA for comprehensive risk assessment, Evagene is designed to play well with it. GEDCOM 5.5.1 export lets a pedigree constructed in Evagene be taken into CanRisk or any other GEDCOM-capable tool. The REST API and webhook layer let downstream systems react to pedigree changes or analysis completions. Nothing in Evagene's design precludes a parallel CanRisk workflow; if your service needs both, you can run both, with Evagene as the pedigree-management layer and CanRisk as the comprehensive-risk tool.

Three Evagene-specific capabilities are worth noting for services that already use BOADICEA. First, batch risk screening runs BRCAPRO, MMRpro, PancPRO, and Mendelian analyses across the 200-plus disease catalogue in a single operation — useful for the "this family has multiple cancers across multiple sites" case that a breast-specific tool does not address. Second, AI interpretation with bring-your-own-key LLMs drafts structured narrative reports combining pedigree findings with risk results, which a clinician reviews. Third, the MCP server and REST API make pedigree data and risk results accessible to AI agents and internal tooling. Docs are at evagene.net/help. Evagene is free during Alpha via the waiting list.

Frequently asked questions

Related reading

• BRCAPRO calculator
• Tyrer-Cuzick alternative
• Breast cancer family history calculator
• Ovarian cancer family history calculator
• Hereditary cancer risk assessment
• Pedigree drawing software
• Clinical genetics pedigree tool
• Mendelian inheritance calculator
• GEDCOM pedigree software
• Phenotips vs Evagene comparison